Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy-Reference-Cited by-同舟云学术

Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving Immunotherapy

Published:2020-02-25 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Garg Saurabh K.,Ott Matthew J.,Mostofa A. G. M.,Chen Zhihua,Chen Y. Ann,Kroeger Jodi,Cao Biwei,Mailloux Adam W.,Agrawal Alisha,Schaible Braydon J.,Sarnaik Amod,Weber Jeffrey S.,Berglund Anders E.,Mulé James J.,Markowitz Joseph

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference63 articles.

1. The future of immune checkpoint therapy;Sharma;Science,2015

2. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy;Topalian;Nat Rev Cancer,2016

3. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

4. flowPeaks: a fast unsupervised clustering for flow cytometry data via K-means and density peak finding;Ge;Bioinformatics,2012

5. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia;Amir el;Nat Biotechnol,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A metabolic perspective on nitric oxide function in melanoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-01

2. Dichotomous Nitric Oxide–Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma;Cancers;2023-03-14

3. Combination of Electrochemistry and Mass Spectrometry to Study Nitric Oxide Metabolism and Its Modulation by Compound K in Breast Cancer Cells;Analytical Chemistry;2022-03-21

4. Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy;Nature Communications;2022-03-18

5. Proteomic biomarker technology for cancer immunotherapy;Engineering Technologies and Clinical Translation;2022